Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 624 results found. Search for [ dcgi ]

Results 1 to 21 of 624
PTI
June 12, 2021
Ram Vishwakarma, the advisor to the CSIR Director-General, said Colchicine, in combination with standard care, will be an important therapeutic intervention for COVID-19 patients with cardiac co-morbidities


PTI
June 12, 2021
NITI Aayog member (Health) V K Paul said each country has its own regulatory system which India respects and hoped that the manufacturer will be able to comply with it by doing whatever requires to be done


PTI
June 11, 2021
The Hyderabad-based firm said it has developed the product which is backward integrated with its in-house API (Active Pharmaceutical Ingredient)


BusinessToday.In
June 9, 2021
Last date to submit EoI applications through email is June 17. EoI submitted by industries will be scrutinised by a Technical Assessment Committe, a DRDO statement said


BusinessToday.In
June 7, 2021
DGCI's approval for Covaxin trials on children was followed by recommendation by the Subject Expert Committee; AIIMS Delhi is not the only hospital to begin Covaxin trials for children


PTI
June 6, 2021
The remarks by the Russian president came a day after officials in New Delhi said the Serum Institute of India has received preliminary approval from the country's drug regulator for manufacturing of Sputnik V


Shailendra Shukla
New Delhi, June 5, 2021
'Publicity': Delhi HC junks Juhi Chawla's suit against 5G; imposes Rs 20-lakh fineThe Delhi High Court on Friday dismissed the lawsuit by actress Juhi Chawla against the implementation of 5G network technology in the country. The court ruled the plea was filed to gain \"publicity\" and that the plaintiffs, Chawla and two others, have abused the process of law. The Delhi High Court has imposed a fine of Rs 20 lakh on the plaintiffs. After the court pronounced the judgement, Chawla's counsel s...


PTI
June 5, 2021
While the firms will continue to make these three vaccines, this action will allow US-based companies that supply these vaccine manufacturers to make their own decisions on which orders to fulfil first


BusinessToday.In
June 4, 2021
There are many colleges and universities in US that are asking students to be revaccinated if they have received vaccines -- like Sputnik V and Covaxin -- that have not received WHO approval.  They are citing a lack of data on efficacy and safety of these vaccines


BusinessToday.In
New Delhi, June 4, 2021
India will receive COVID vaccines from the United States and this news was communicated to PM Modi by US Vice President Kamala Harris in her first phone call to him. The Biden-Harris administration's framework looks to share at least 80 million vaccines globally by the end of June. This will be a part of the US strategy on global vaccine sharing. Vice President Harris has been calling Heads of States and communicating the Global Allocation Plan for the first 25 million doses. PM Modi tweeted after the call, appreciating the US for its assurance of vaccine supplies. Watch the video for more.Also Read: DCGI approves Serum's request to manufacture Sputnik V COVID-19 vaccine in India


BusinessToday.In
New Delhi, June 4, 2021
A study by the central government on the devastating second COVID wave has revealed that despite Delhiites having sero positivity of over 56 per cent, they got little protection against the Delta variant that took over the national capital March 2021 onwards. The study was conducted by scientists of INSACOG (the consortium of labs undertaking genome sequencing in India) and National Centre for Disease Control (NCDC). The rise in prevalence of the Delta variant was accompanied by a corresponding rise in the overall positivity rate. Watch the video for more on this variant.Also Read: DCGI approves Serum's request to manufacture Sputnik V COVID-19 vaccine in India


BusinessToday.In
June 4, 2021
Due non-availability of normal commercial flight operations a number of foreign nationals who came to India prior to March 2020 on valid Indian visas have remained stranded in India


BusinessToday.In
June 4, 2021
Pune-based SII has partnered with Gamaleya Research Institute of Epidemiology and Microbiology, Moscow, in Russia for developing Sputnik V COVID-19 vaccine in India at its licensed facility in Hadapsar


BusinessToday.In
New Delhi, June 3, 2021
Pune-based Serum Institute of India (SII) has applied to the Drug Controller General of India (DCGI) seeking permission to manufacture COVID-19 vaccine Sputnik V in the country, government sources said on Thursday. Russia's RDIF sovereign wealth fund, which is marketing Sputnik V globally, has already signed agreements with six leading Indian manufacturers including Dr Reddy's Laboratories, Gland Pharma, Hetero Biopharma, Panacea Biotec, Stelis Biopharma and Virchow Biotech. The vaccine is currently being manufactured in India by Dr Reddy's Laboratories. The SII has also sought approval for test analysis and examination. Once permitted, the company will need to conduct clinical trials. Watch the video for more.Also Read: Serum Institute seeks nod for licence to manufacture Sputnik V in India


BusinessToday.In
June 3, 2021
Foreign pharma majors, such as Pfizer and Moderna, have said that they will export their COVID-19 vaccines to India only if the deal is the Indian government and the company is guarded against legal cases for any severe side effects


BusinessToday.In
June 3, 2021
Once the company gets permission, it will have to conduct clinical trials and if successful, the Serum Institute will become the seventh company to manufacture Sputnik V


PB Jayakumar
June 2, 2021
The acquisition of Akorn India helped Biological E create a potential overall manufacturing capacity of over 1 billion doses per annum.


BusinessToday.In
June 2, 2021
Like other nations, the Indian government is also expected to grant indemnity to foreign drugmakers like Pfizer and Moderna if they seek drug regulator's nod for the Emergency Use Authorisation (EUA)


PB Jayakumar
June 2, 2021
DCGI said the requirement of conducting post approval bridging clinical trials and requirement of testing of every batch of vaccine by the CDL can be exempted, if the vaccine lot/batch is certified and released by National Control Laboratory of country of origin


PTI
June 1, 2021
The hospital is administering a combination of casirivimab and imdevimab to consenting patients with mild and moderate COVID-19 symptoms at high risk of developing serious illness


PAGES 1 OF 32  12345